Cargando…
Use of immunohistochemical markers can refine prognosis in triple negative breast cancer
BACKGROUND: Basal-like breast cancer has been extensively characterized on the basis of gene expression profiles, but it is becoming increasingly common for these tumors to be defined on the basis of immunohistochemical (IHC) staining patterns, particularly in retrospective studies where material fo...
Autores principales: | , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1948892/ https://www.ncbi.nlm.nih.gov/pubmed/17650314 http://dx.doi.org/10.1186/1471-2407-7-134 |
_version_ | 1782134511344025600 |
---|---|
author | Tischkowitz, Marc Brunet, Jean-Sébastien Bégin, Louis R Huntsman, David G Cheang, Maggie CU Akslen, Lars A Nielsen, Torsten O Foulkes, William D |
author_facet | Tischkowitz, Marc Brunet, Jean-Sébastien Bégin, Louis R Huntsman, David G Cheang, Maggie CU Akslen, Lars A Nielsen, Torsten O Foulkes, William D |
author_sort | Tischkowitz, Marc |
collection | PubMed |
description | BACKGROUND: Basal-like breast cancer has been extensively characterized on the basis of gene expression profiles, but it is becoming increasingly common for these tumors to be defined on the basis of immunohistochemical (IHC) staining patterns, particularly in retrospective studies where material for expression profiling may not be available. The IHC pattern that best defines basal-like tumors is under investigation and various combinations of ER, PR, HER2-, CK5/6+ and EGFR+ have been tested. METHODS: Using datasets from two different hospitals we describe how using different combinations of immunohistochemical patterns has different effects on estimating prognosis at different time intervals after diagnosis. As our baseline, we used two IHC patterns ER-/PR-/HER2-("triple negative phenotype", TNP) and ER-/HER2-/CK5/6+ and/or EGFR+ ("core basal phenotype", CBP). RESULTS: There was no overall difference in survival between the two hospital-based series, but there was a difference between the TNP and non-TNP groups which was most marked at 3 years (76.8% vs 93.5%, p < .0001). This difference reduced with time, suggesting that long term survivors (beyond 10 years) in the TNP group may have comparable survival to non-TNP cases. A similar difference was seen if CBP was used instead of TNP. However when CK5/6 and/or EGFR expressing tumors were analyzed without consideration of ER/PR status, the reduction in survival increased with time, becoming more pronounced at 10 years than at 3 years. CONCLUSION: Our findings suggests that CK5/6 and/or EGFR expressing tumor types have a persistently poorer prognosis over the longer term, an observation that may have important therapeutic implications as drugs that target the EGFR are currently being evaluated in breast cancer. |
format | Text |
id | pubmed-1948892 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2007 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-19488922007-08-15 Use of immunohistochemical markers can refine prognosis in triple negative breast cancer Tischkowitz, Marc Brunet, Jean-Sébastien Bégin, Louis R Huntsman, David G Cheang, Maggie CU Akslen, Lars A Nielsen, Torsten O Foulkes, William D BMC Cancer Research Article BACKGROUND: Basal-like breast cancer has been extensively characterized on the basis of gene expression profiles, but it is becoming increasingly common for these tumors to be defined on the basis of immunohistochemical (IHC) staining patterns, particularly in retrospective studies where material for expression profiling may not be available. The IHC pattern that best defines basal-like tumors is under investigation and various combinations of ER, PR, HER2-, CK5/6+ and EGFR+ have been tested. METHODS: Using datasets from two different hospitals we describe how using different combinations of immunohistochemical patterns has different effects on estimating prognosis at different time intervals after diagnosis. As our baseline, we used two IHC patterns ER-/PR-/HER2-("triple negative phenotype", TNP) and ER-/HER2-/CK5/6+ and/or EGFR+ ("core basal phenotype", CBP). RESULTS: There was no overall difference in survival between the two hospital-based series, but there was a difference between the TNP and non-TNP groups which was most marked at 3 years (76.8% vs 93.5%, p < .0001). This difference reduced with time, suggesting that long term survivors (beyond 10 years) in the TNP group may have comparable survival to non-TNP cases. A similar difference was seen if CBP was used instead of TNP. However when CK5/6 and/or EGFR expressing tumors were analyzed without consideration of ER/PR status, the reduction in survival increased with time, becoming more pronounced at 10 years than at 3 years. CONCLUSION: Our findings suggests that CK5/6 and/or EGFR expressing tumor types have a persistently poorer prognosis over the longer term, an observation that may have important therapeutic implications as drugs that target the EGFR are currently being evaluated in breast cancer. BioMed Central 2007-07-24 /pmc/articles/PMC1948892/ /pubmed/17650314 http://dx.doi.org/10.1186/1471-2407-7-134 Text en Copyright © 2007 Tischkowitz et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Tischkowitz, Marc Brunet, Jean-Sébastien Bégin, Louis R Huntsman, David G Cheang, Maggie CU Akslen, Lars A Nielsen, Torsten O Foulkes, William D Use of immunohistochemical markers can refine prognosis in triple negative breast cancer |
title | Use of immunohistochemical markers can refine prognosis in triple negative breast cancer |
title_full | Use of immunohistochemical markers can refine prognosis in triple negative breast cancer |
title_fullStr | Use of immunohistochemical markers can refine prognosis in triple negative breast cancer |
title_full_unstemmed | Use of immunohistochemical markers can refine prognosis in triple negative breast cancer |
title_short | Use of immunohistochemical markers can refine prognosis in triple negative breast cancer |
title_sort | use of immunohistochemical markers can refine prognosis in triple negative breast cancer |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1948892/ https://www.ncbi.nlm.nih.gov/pubmed/17650314 http://dx.doi.org/10.1186/1471-2407-7-134 |
work_keys_str_mv | AT tischkowitzmarc useofimmunohistochemicalmarkerscanrefineprognosisintriplenegativebreastcancer AT brunetjeansebastien useofimmunohistochemicalmarkerscanrefineprognosisintriplenegativebreastcancer AT beginlouisr useofimmunohistochemicalmarkerscanrefineprognosisintriplenegativebreastcancer AT huntsmandavidg useofimmunohistochemicalmarkerscanrefineprognosisintriplenegativebreastcancer AT cheangmaggiecu useofimmunohistochemicalmarkerscanrefineprognosisintriplenegativebreastcancer AT akslenlarsa useofimmunohistochemicalmarkerscanrefineprognosisintriplenegativebreastcancer AT nielsentorsteno useofimmunohistochemicalmarkerscanrefineprognosisintriplenegativebreastcancer AT foulkeswilliamd useofimmunohistochemicalmarkerscanrefineprognosisintriplenegativebreastcancer |